Lexaria Bioscience (LEXX) announced that its contract research organization has completed the study milestone known as last patent last visit in Lexaria’s Phase 1b glucagon-like peptide-1 study in Australia, GLP-1-H24-4.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEXX:
- Lexaria Bioscience announces last patient, last visit in Phase 1b GLP-1 study
- Lexaria Bioscience Targets GLP-1 Market with DehydraTECH Innovation
- Buy Recommendation for Lexaria Bioscience Based on Improved Safety Profile of DehydraTECH-semaglutide
- Lexaria Bioscience price target lowered to $4 from $5 at H.C. Wainwright
- Lexaria Bioscience Reports Promising Interim Results in GLP-1 Study